IceCure Medical Ltd.

IceCure Medical Ltd. is a commercial-stage medical device company dedicated to the research, development, and marketing of cryoablation systems and technologies for the treatment of tumors. Headquartered in Caesarea, Israel, the company's mission is to transform healthcare by expanding patient and provider choice through advanced, minimally invasive cryoablation options for both benign and malignant tumors.

The company's flagship product is the ProSense® Cryoablation System, which utilizes liquid nitrogen to destroy tumors by freezing them. This minimally invasive technology is applied across various clinical indications, including breast tumors (both cancerous and fibroadenomas), kidney cancer, lung cancer, and for palliative care. IceCure also develops the IceSense3 system for broader ablation applications and is working on XSense and MSense systems for single and multi-probe treatments. Its systems are distributed to hospitals, interventional radiological centers, ambulatory centers, and private clinics in markets such as the United States, Japan, India, China, and Israel.

In late 2025, IceCure Medical achieved a significant milestone by receiving FDA marketing authorization for its ProSense system for the local treatment of early-stage, low-risk breast cancer in women aged 70 and over. The company recently announced a 1-for-30 reverse share split to support Nasdaq compliance. Eyal Shamir serves as the Chief Executive Officer, and Meir Peleg was appointed Chief Financial Officer effective May 17, 2026. IceCure continues to pursue global expansion, with recent regulatory approval in India and a filing for approval in China for its cryoablation technology.